SPRO: FDA approval, immunology pivot, and $105M financing extend cash runway into 2029
Automated news aggregation. Headlines and summaries are gathered from public feeds; see our editorial standards for sourcing, corrections, and AI-assist disclosure.
Related coverage: SPRO: FDA approval, immunology pivot, and $105M financing extend cash runway into 2029 TradingView
Advertisement
About this story
This story was aggregated from TradingView. Headlines, summaries, and links are gathered automatically from public RSS feeds for your convenience.
Read the full story →For agents:JSON recordOpenAPIWebMCPllms.txt